<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35094290</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1556-2891</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>18</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Forensic science, medicine, and pathology</Title>
          <ISOAbbreviation>Forensic Sci Med Pathol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Examination of multiple drug arrests reported to the Maine Diversion Alert Program.</ArticleTitle>
        <Pagination>
          <StartPage>133</StartPage>
          <EndPage>140</EndPage>
          <MedlinePgn>133-140</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s12024-021-00454-1</ELocationID>
        <Abstract>
          <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Much of the responsibility for the increasing drug overdoses in the US has been attributed to opioids but most opioid overdoses also involve another drug. The objective of this study was to identify the drugs involved in polysubstance arrests. The substances that were more likely to be found in conjunction with other substances, using the drug arrests reported to Maine's Diversion Alert Program (DAP) were examined.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Single and multiple drug arrests were quantified (N = 9,216). Multiple drug arrest percentages were compared to single drug arrest percentages to create a Multiple-to-Single Ratio (MSR) specific to each drug family and each drug to identify over (MSR &gt; 1) and under-representation (MSR &lt; 1).</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Over three-fifths (63.8%) of all arrests involved a single drug. Opioids accounted for over-half (53.5%) of single arrests, followed by stimulants (27.7%) and hallucinogens (7.7%). Similarly, nearly two-fifths (39.6%) of multiple arrests were for opioids, followed by stimulants (30.8%) and miscellaneous (13.0%). Miscellaneous psychoactive prescription substances (e.g. clonidine, gabapentin, cyclobenzaprine, hydroxyzine) had the highest (1.51) MSR of any drug family. Conversely, stimulants (0.63), opioids (0.42), and hallucinogens (0.35) were significantly underrepresented in polysubstance arrests. Carisoprodol (8.80), amitriptyline (6.34), and quetiapine (4.69) had the highest MSR. Bath-salts (0.34), methamphetamine (0.44), and oxycodone (0.54) had the lowest MSR.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The misuse of opioids, both alone and in conjunction with another drug, deserves continued surveillance. In addition, common prescription drugs with less appreciated misuse potential, especially carisoprodol, amitriptyline, and quetiapine, require greater attention for their ability to enhance the effects of other drugs.</AbstractText>
          <CopyrightInformation>© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Siddiqui</LastName>
            <ForeName>Maaz Z</ForeName>
            <Initials>MZ</Initials>
            <AffiliationInfo>
              <Affiliation>University of Scranton, Scranton, PA, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Geisinger Commonwealth School of Medicine, Scranton, PA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Piserchio</LastName>
            <ForeName>John P</ForeName>
            <Initials>JP</Initials>
            <AffiliationInfo>
              <Affiliation>Geisinger Commonwealth School of Medicine, Scranton, PA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Patel</LastName>
            <ForeName>Misha</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Geisinger Commonwealth School of Medicine, Scranton, PA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Park</LastName>
            <ForeName>Jino</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Geisinger Commonwealth School of Medicine, Scranton, PA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Foster</LastName>
            <ForeName>Michelle L</ForeName>
            <Initials>ML</Initials>
            <AffiliationInfo>
              <Affiliation>Diversion Alert, Houlton, ME, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Desrosiers</LastName>
            <ForeName>Clare E</ForeName>
            <Initials>CE</Initials>
            <AffiliationInfo>
              <Affiliation>Diversion Alert, Houlton, ME, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Herbert</LastName>
            <ForeName>John</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Diversion Alert, Houlton, ME, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nichols</LastName>
            <ForeName>Stephanie D</ForeName>
            <Initials>SD</Initials>
            <AffiliationInfo>
              <Affiliation>University of New England, Portland, ME, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>McCall</LastName>
            <ForeName>Kenneth L</ForeName>
            <Initials>KL</Initials>
            <AffiliationInfo>
              <Affiliation>University of New England, Portland, ME, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Piper</LastName>
            <ForeName>Brian J</ForeName>
            <Initials>BJ</Initials>
            <AffiliationInfo>
              <Affiliation>Geisinger Commonwealth School of Medicine, Scranton, PA, USA. psy391@gmail.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center for Pharmacy Innovation and Outcomes, Forty Fort, PA, USA. psy391@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>01</Month>
          <Day>30</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Forensic Sci Med Pathol</MedlineTA>
        <NlmUniqueID>101236111</NlmUniqueID>
        <ISSNLinking>1547-769X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000701">Analgesics, Opioid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000697">Central Nervous System Stimulants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006213">Hallucinogens</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>1806D8D52K</RegistryNumber>
          <NameOfSubstance UI="D000639">Amitriptyline</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>21925K482H</RegistryNumber>
          <NameOfSubstance UI="D002328">Carisoprodol</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>2S3PL1B6UJ</RegistryNumber>
          <NameOfSubstance UI="D000069348">Quetiapine Fumarate</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000639" MajorTopicYN="N">Amitriptyline</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000701" MajorTopicYN="N">Analgesics, Opioid</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002328" MajorTopicYN="Y">Carisoprodol</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000697" MajorTopicYN="Y">Central Nervous System Stimulants</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D062787" MajorTopicYN="Y">Drug Overdose</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006213" MajorTopicYN="Y">Hallucinogens</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008281" MajorTopicYN="N" Type="Geographic">Maine</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D063487" MajorTopicYN="Y">Prescription Drug Misuse</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069348" MajorTopicYN="N">Quetiapine Fumarate</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Addiction</Keyword>
        <Keyword MajorTopicYN="N">Drug misuse</Keyword>
        <Keyword MajorTopicYN="N">Opioids</Keyword>
        <Keyword MajorTopicYN="N">Stimulants</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>30</Day>
          <Hour>20</Hour>
          <Minute>38</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35094290</ArticleId>
        <ArticleId IdType="doi">10.1007/s12024-021-00454-1</ArticleId>
        <ArticleId IdType="pii">10.1007/s12024-021-00454-1</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Katz J, Sanger-Katz M. It’s huge, it’s historic, it’s unheard of’: The spike in overdose deaths. NY Times 7/14/21. https://www.nytimes.com/interactive/2021/07/14/upshot/drug-overdose-deaths.html . Accessed 19 Aug 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>National Institute on Drug Abuse. Overdose death rates. National Institutes of Health. 2020;2018.</Citation>
        </Reference>
        <Reference>
          <Citation>Jones CM, Einstein EB, Compton WM. Changes in synthetic opioid involvement in drug overdose deaths in the United States, 2010–2016. JAMA. 2018;319:1819–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2018.2844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barocas JA, Wang J, Marshall BDL, LaRochelle MR, Bettano A, Bernson D, et al. Sociodemographic factors and social determinants associated with toxicology confirmed polysubstance opioid-related deaths. Drug Alcohol Depend. 2019;200:59–63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.drugalcdep.2019.03.014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hyde TF, Bekoe-Tabiri AD, Kropp Lopez AK, Devia LG, Gutierrez BD, Lara MC, et al. County and demographic differences in drug arrests and controlled substance use in Maine. J Maine Medical Center. 2021;3:2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.46804/2641-2225.1074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin SL, Desrosiers C. Diversion Alert: 1-year evaluation across Northern New England, 2013–2014. Prev Chronic Dis. 2016;13:e159.</Citation>
        </Reference>
        <Reference>
          <Citation>McCall K, Nichols SD, Holt C, Ochs L, Cattabriga G, Tu C. Prescription Monitoring Program trends among individuals arrested in Maine for trafficking prescription drugs in 2014. Pharmacotherapy. 2016;36:585–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/phar.1758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Piper BJ, Desrosiers CE, Lipovsky JW, Rodney MA, Baker RP, McCall KL, et al. Use and misuse of opioids in Maine: Results from pharmacists, the Prescription Monitoring, and the Diversion Alert Programs. J Stud Alcohol Drugs. 2016;77:556–65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.15288/jsad.2016.77.556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Piper BJ, Desrosiers CE, Fisher HC, McCall KL, Nichols SD. A new tool to tackle the opioid epidemic: Description, utility, and results from the Maine Diversion Alert Program. Pharmacotherapy. 2017;37:791–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/phar.1952</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Piper BJ, Suarez MJ, Piserchio JP, Shah DT, Simoyan OM, McCall KL, et al. Illicit and prescription drug misuse as reported to the Maine Diversion Alert Program. Forensic Sci Int. 2018;285:65–71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.forsciint.2018.01.025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simpson KJ, Moran MT, Foster ML, Shah DT, Chung DY, Nichols SD, et al. Descriptive, observational study of pharmaceutical and non-pharmaceutical arrests, use, and overdoses in Maine. BMJ Open. 2019;9:e027117.</Citation>
        </Reference>
        <Reference>
          <Citation>Simpson KJ, Moran MT, McCall KL, Herbert J, Foster ML, Simoyan OM, et al. Increasing heroin, cocaine, and buprenorphine arrests reported to the Maine Diversion Alert Program. Forensic Sci Int. 2019;303:109924.v</Citation>
        </Reference>
        <Reference>
          <Citation>Campbell L, Coomer L, Jacob G, Lenz R. Gabapentin controlled substance status. J Am Pharm Assoc. 2021;S1544–3191(21):00027–33.</Citation>
        </Reference>
        <Reference>
          <Citation>Huang X, Keyes KM, Li G. Increasing prescription opioid and heroin overdose mortality in the United States, 1999–2014: An age-period-cohort analysis. Am J Public Health. 2018;108:131–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2105/AJPH.2017.304142</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bryson HM, Wilde MI. Amitriptyline. A review of its pharmacological properties and therapeutic use in chronic pain states. Drugs Aging. 1996;8:458–76.</Citation>
        </Reference>
        <Reference>
          <Citation>Delisle JD. A case of amitriptyline abuse. Am J Psychiatry. 1990;147:1377–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2400006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wohlreich MM, Welch W. Amitriptyline abuse presenting as acute toxicity. Psychosomatics. 1993;34:191–3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0033-3182(93)71918-0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sein AJ, Chodorowski Z, Habrat B. Recreational amitriptyline abuse. Przegla̧d lekarski. 2005;62:397–8.</Citation>
        </Reference>
        <Reference>
          <Citation>Prahlow JA, Landrum JE. Amitriptyline abuse and misuse. Am J Forensic Med Pathology. 2005;26:81–6.</Citation>
        </Reference>
        <Reference>
          <Citation>Cohen MJ, Hanbury R, Stimmel B. Abuse of amitriptyline. JAMA. 1978;240:1372–3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.1978.03290130066024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Horsfall JT, Sprague JE. Pharmacology and toxicology of the ‘holy trinity.’ Basic Clin Pharmacol Toxicol. 2017;120:115–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bcpt.12655</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun C, Hollenbach KA, Cantrell FL. Trends in carisoprodol abuse and misuse after regulatory scheduling: A retrospective review of California poison control calls from 2008 to 2015. Clin Tox. 2018;56:653–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/15563650.2017.1414950</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hedegaard H, Bastian BA, Trinidad JP, Spencer M, Warner M. Drugs most frequently involved in drug overdose deaths: United States, 2011–2016. Natl Vital Stat Rep. 2018;67:1–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30707673</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maan J, Ershadi M, Khan I, Saadabadi A. Quetiapine. Treasure Island: StatPearls; 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Kim S, Lee G, Kim E, Jung H, Chang J. Quetiapine misuse and abuse: Is it an atypical paradigm of drug seeking behavior? J Research Pharmacy Pract. 2017;6:12–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4103/2279-042X.200987</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pinta ER, Taylor RE. Quetiapine addiction? Am J Psychiatry. 2007;164:174–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1176/ajp.2007.164.1.174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Piróg-Balcerzak A, Habrat B, Mierzejewski P. Misuse and abuse of quetiapine. Psychiatr Pol. 2015;49:81–93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.12740/PP/32923</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andersen FD, Simonsen U, Andersen CU. Quetiapine and other antipsychotics combined with opioids in legal autopsy cases: A random finding or cause of fatal outcome? Basic Clin Pharmacol Toxicol. 2021;128:66–79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bcpt.13480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Collins LK, Pande LJ, Chung DY, Nichols SD, McCall KL, Piper BJ. Trends in the medical supply of fentanyl and fentanyl analogues: United States, 2006 to 2017. Prev Med. 2019;123:95–100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ypmed.2019.02.017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pashmineh Azar AR, Cruz-Mullane A, Podd JC, Lam WS, Kaleem SH, Lockard LB, et al. Rise and regional disparities in buprenorphine utilization in the United States. Pharmacoepidemiol Drug Saf. 2020;29:708–15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/pds.4984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bennett AS, Elliott L. Naloxone’s role in the national opioid crisis-past struggles, current efforts, and future opportunities. Transl Res. 2021;234:43–57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.trsl.2021.03.001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McGowan CR, Harris M, Platt L, Hope V, Rhodes T. Fentanyl self-testing outside supervised injection settings to prevent opioid overdose: Do we know enough to promote it? Int J Drug Policy. 2018;58:31–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.drugpo.2018.04.017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levengood TW, Yoon GH, Davoust MJ, Ogden SN, Marshall BDN, Cahill SR, et al. Supervised injection facilities as harm reduction: A systematic review. Am J Prev Med. 2021;61:738–49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.amepre.2021.04.017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prescription Drug Monitoring Program Training and Technical Assistance Center, State PDMP profiles and contacts. https://www.pdmpassist.org/State . Accessed 25 Nov 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Gabrielson R, Sanders T. How a $2 roadside drug test sends innocent people to jail. New York Times, July 10, 2016, MM34. http://www.nytimes.com/2016/07/10/magazine/how-a-2-roadside-drug-test-sends-innocent-people-to-jail.html?_r=0 . Accessed 25 Nov 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>American Psychiatric Association: Diagnostic and statistical manual of mental disorders, Fifth edition. Arlington, VA: American Psychiatric Association; 2013.</Citation>
        </Reference>
        <Reference>
          <Citation>International Association of Chiefs of Police. Law enforcement code of ethics. https://www.theiacp.org/resources/law-enforcement-code-of-ethics#:~:text=As%20a%20law%20enforcement%20officer,all%20to%20liberty%2C%20equality%2C%20and . Accessed 26 Nov 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Shefner RT, Sloan JS, Sandler KR, Anderson ED. Missed opportunities: Arrest and court touchpoints for individuals who fatally overdosed in Philadelphia in 2016. Int J Drug Policy. 2020;78:102724.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35094290</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1556-2891</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>18</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Forensic science, medicine, and pathology</Title>
          <ISOAbbreviation>Forensic Sci Med Pathol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Examination of multiple drug arrests reported to the Maine Diversion Alert Program.</ArticleTitle>
        <Pagination>
          <StartPage>133</StartPage>
          <EndPage>140</EndPage>
          <MedlinePgn>133-140</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s12024-021-00454-1</ELocationID>
        <Abstract>
          <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Much of the responsibility for the increasing drug overdoses in the US has been attributed to opioids but most opioid overdoses also involve another drug. The objective of this study was to identify the drugs involved in polysubstance arrests. The substances that were more likely to be found in conjunction with other substances, using the drug arrests reported to Maine's Diversion Alert Program (DAP) were examined.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Single and multiple drug arrests were quantified (N = 9,216). Multiple drug arrest percentages were compared to single drug arrest percentages to create a Multiple-to-Single Ratio (MSR) specific to each drug family and each drug to identify over (MSR &gt; 1) and under-representation (MSR &lt; 1).</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Over three-fifths (63.8%) of all arrests involved a single drug. Opioids accounted for over-half (53.5%) of single arrests, followed by stimulants (27.7%) and hallucinogens (7.7%). Similarly, nearly two-fifths (39.6%) of multiple arrests were for opioids, followed by stimulants (30.8%) and miscellaneous (13.0%). Miscellaneous psychoactive prescription substances (e.g. clonidine, gabapentin, cyclobenzaprine, hydroxyzine) had the highest (1.51) MSR of any drug family. Conversely, stimulants (0.63), opioids (0.42), and hallucinogens (0.35) were significantly underrepresented in polysubstance arrests. Carisoprodol (8.80), amitriptyline (6.34), and quetiapine (4.69) had the highest MSR. Bath-salts (0.34), methamphetamine (0.44), and oxycodone (0.54) had the lowest MSR.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The misuse of opioids, both alone and in conjunction with another drug, deserves continued surveillance. In addition, common prescription drugs with less appreciated misuse potential, especially carisoprodol, amitriptyline, and quetiapine, require greater attention for their ability to enhance the effects of other drugs.</AbstractText>
          <CopyrightInformation>© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Siddiqui</LastName>
            <ForeName>Maaz Z</ForeName>
            <Initials>MZ</Initials>
            <AffiliationInfo>
              <Affiliation>University of Scranton, Scranton, PA, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Geisinger Commonwealth School of Medicine, Scranton, PA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Piserchio</LastName>
            <ForeName>John P</ForeName>
            <Initials>JP</Initials>
            <AffiliationInfo>
              <Affiliation>Geisinger Commonwealth School of Medicine, Scranton, PA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Patel</LastName>
            <ForeName>Misha</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Geisinger Commonwealth School of Medicine, Scranton, PA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Park</LastName>
            <ForeName>Jino</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Geisinger Commonwealth School of Medicine, Scranton, PA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Foster</LastName>
            <ForeName>Michelle L</ForeName>
            <Initials>ML</Initials>
            <AffiliationInfo>
              <Affiliation>Diversion Alert, Houlton, ME, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Desrosiers</LastName>
            <ForeName>Clare E</ForeName>
            <Initials>CE</Initials>
            <AffiliationInfo>
              <Affiliation>Diversion Alert, Houlton, ME, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Herbert</LastName>
            <ForeName>John</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Diversion Alert, Houlton, ME, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nichols</LastName>
            <ForeName>Stephanie D</ForeName>
            <Initials>SD</Initials>
            <AffiliationInfo>
              <Affiliation>University of New England, Portland, ME, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>McCall</LastName>
            <ForeName>Kenneth L</ForeName>
            <Initials>KL</Initials>
            <AffiliationInfo>
              <Affiliation>University of New England, Portland, ME, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Piper</LastName>
            <ForeName>Brian J</ForeName>
            <Initials>BJ</Initials>
            <AffiliationInfo>
              <Affiliation>Geisinger Commonwealth School of Medicine, Scranton, PA, USA. psy391@gmail.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center for Pharmacy Innovation and Outcomes, Forty Fort, PA, USA. psy391@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>01</Month>
          <Day>30</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Forensic Sci Med Pathol</MedlineTA>
        <NlmUniqueID>101236111</NlmUniqueID>
        <ISSNLinking>1547-769X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000701">Analgesics, Opioid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000697">Central Nervous System Stimulants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006213">Hallucinogens</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>1806D8D52K</RegistryNumber>
          <NameOfSubstance UI="D000639">Amitriptyline</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>21925K482H</RegistryNumber>
          <NameOfSubstance UI="D002328">Carisoprodol</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>2S3PL1B6UJ</RegistryNumber>
          <NameOfSubstance UI="D000069348">Quetiapine Fumarate</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000639" MajorTopicYN="N">Amitriptyline</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000701" MajorTopicYN="N">Analgesics, Opioid</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002328" MajorTopicYN="Y">Carisoprodol</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000697" MajorTopicYN="Y">Central Nervous System Stimulants</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D062787" MajorTopicYN="Y">Drug Overdose</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006213" MajorTopicYN="Y">Hallucinogens</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008281" MajorTopicYN="N" Type="Geographic">Maine</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D063487" MajorTopicYN="Y">Prescription Drug Misuse</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069348" MajorTopicYN="N">Quetiapine Fumarate</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Addiction</Keyword>
        <Keyword MajorTopicYN="N">Drug misuse</Keyword>
        <Keyword MajorTopicYN="N">Opioids</Keyword>
        <Keyword MajorTopicYN="N">Stimulants</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>30</Day>
          <Hour>20</Hour>
          <Minute>38</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35094290</ArticleId>
        <ArticleId IdType="doi">10.1007/s12024-021-00454-1</ArticleId>
        <ArticleId IdType="pii">10.1007/s12024-021-00454-1</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Katz J, Sanger-Katz M. It’s huge, it’s historic, it’s unheard of’: The spike in overdose deaths. NY Times 7/14/21. https://www.nytimes.com/interactive/2021/07/14/upshot/drug-overdose-deaths.html . Accessed 19 Aug 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>National Institute on Drug Abuse. Overdose death rates. National Institutes of Health. 2020;2018.</Citation>
        </Reference>
        <Reference>
          <Citation>Jones CM, Einstein EB, Compton WM. Changes in synthetic opioid involvement in drug overdose deaths in the United States, 2010–2016. JAMA. 2018;319:1819–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2018.2844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barocas JA, Wang J, Marshall BDL, LaRochelle MR, Bettano A, Bernson D, et al. Sociodemographic factors and social determinants associated with toxicology confirmed polysubstance opioid-related deaths. Drug Alcohol Depend. 2019;200:59–63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.drugalcdep.2019.03.014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hyde TF, Bekoe-Tabiri AD, Kropp Lopez AK, Devia LG, Gutierrez BD, Lara MC, et al. County and demographic differences in drug arrests and controlled substance use in Maine. J Maine Medical Center. 2021;3:2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.46804/2641-2225.1074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin SL, Desrosiers C. Diversion Alert: 1-year evaluation across Northern New England, 2013–2014. Prev Chronic Dis. 2016;13:e159.</Citation>
        </Reference>
        <Reference>
          <Citation>McCall K, Nichols SD, Holt C, Ochs L, Cattabriga G, Tu C. Prescription Monitoring Program trends among individuals arrested in Maine for trafficking prescription drugs in 2014. Pharmacotherapy. 2016;36:585–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/phar.1758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Piper BJ, Desrosiers CE, Lipovsky JW, Rodney MA, Baker RP, McCall KL, et al. Use and misuse of opioids in Maine: Results from pharmacists, the Prescription Monitoring, and the Diversion Alert Programs. J Stud Alcohol Drugs. 2016;77:556–65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.15288/jsad.2016.77.556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Piper BJ, Desrosiers CE, Fisher HC, McCall KL, Nichols SD. A new tool to tackle the opioid epidemic: Description, utility, and results from the Maine Diversion Alert Program. Pharmacotherapy. 2017;37:791–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/phar.1952</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Piper BJ, Suarez MJ, Piserchio JP, Shah DT, Simoyan OM, McCall KL, et al. Illicit and prescription drug misuse as reported to the Maine Diversion Alert Program. Forensic Sci Int. 2018;285:65–71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.forsciint.2018.01.025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simpson KJ, Moran MT, Foster ML, Shah DT, Chung DY, Nichols SD, et al. Descriptive, observational study of pharmaceutical and non-pharmaceutical arrests, use, and overdoses in Maine. BMJ Open. 2019;9:e027117.</Citation>
        </Reference>
        <Reference>
          <Citation>Simpson KJ, Moran MT, McCall KL, Herbert J, Foster ML, Simoyan OM, et al. Increasing heroin, cocaine, and buprenorphine arrests reported to the Maine Diversion Alert Program. Forensic Sci Int. 2019;303:109924.v</Citation>
        </Reference>
        <Reference>
          <Citation>Campbell L, Coomer L, Jacob G, Lenz R. Gabapentin controlled substance status. J Am Pharm Assoc. 2021;S1544–3191(21):00027–33.</Citation>
        </Reference>
        <Reference>
          <Citation>Huang X, Keyes KM, Li G. Increasing prescription opioid and heroin overdose mortality in the United States, 1999–2014: An age-period-cohort analysis. Am J Public Health. 2018;108:131–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2105/AJPH.2017.304142</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bryson HM, Wilde MI. Amitriptyline. A review of its pharmacological properties and therapeutic use in chronic pain states. Drugs Aging. 1996;8:458–76.</Citation>
        </Reference>
        <Reference>
          <Citation>Delisle JD. A case of amitriptyline abuse. Am J Psychiatry. 1990;147:1377–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2400006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wohlreich MM, Welch W. Amitriptyline abuse presenting as acute toxicity. Psychosomatics. 1993;34:191–3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0033-3182(93)71918-0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sein AJ, Chodorowski Z, Habrat B. Recreational amitriptyline abuse. Przegla̧d lekarski. 2005;62:397–8.</Citation>
        </Reference>
        <Reference>
          <Citation>Prahlow JA, Landrum JE. Amitriptyline abuse and misuse. Am J Forensic Med Pathology. 2005;26:81–6.</Citation>
        </Reference>
        <Reference>
          <Citation>Cohen MJ, Hanbury R, Stimmel B. Abuse of amitriptyline. JAMA. 1978;240:1372–3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.1978.03290130066024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Horsfall JT, Sprague JE. Pharmacology and toxicology of the ‘holy trinity.’ Basic Clin Pharmacol Toxicol. 2017;120:115–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bcpt.12655</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun C, Hollenbach KA, Cantrell FL. Trends in carisoprodol abuse and misuse after regulatory scheduling: A retrospective review of California poison control calls from 2008 to 2015. Clin Tox. 2018;56:653–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/15563650.2017.1414950</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hedegaard H, Bastian BA, Trinidad JP, Spencer M, Warner M. Drugs most frequently involved in drug overdose deaths: United States, 2011–2016. Natl Vital Stat Rep. 2018;67:1–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30707673</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maan J, Ershadi M, Khan I, Saadabadi A. Quetiapine. Treasure Island: StatPearls; 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Kim S, Lee G, Kim E, Jung H, Chang J. Quetiapine misuse and abuse: Is it an atypical paradigm of drug seeking behavior? J Research Pharmacy Pract. 2017;6:12–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4103/2279-042X.200987</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pinta ER, Taylor RE. Quetiapine addiction? Am J Psychiatry. 2007;164:174–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1176/ajp.2007.164.1.174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Piróg-Balcerzak A, Habrat B, Mierzejewski P. Misuse and abuse of quetiapine. Psychiatr Pol. 2015;49:81–93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.12740/PP/32923</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andersen FD, Simonsen U, Andersen CU. Quetiapine and other antipsychotics combined with opioids in legal autopsy cases: A random finding or cause of fatal outcome? Basic Clin Pharmacol Toxicol. 2021;128:66–79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bcpt.13480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Collins LK, Pande LJ, Chung DY, Nichols SD, McCall KL, Piper BJ. Trends in the medical supply of fentanyl and fentanyl analogues: United States, 2006 to 2017. Prev Med. 2019;123:95–100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ypmed.2019.02.017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pashmineh Azar AR, Cruz-Mullane A, Podd JC, Lam WS, Kaleem SH, Lockard LB, et al. Rise and regional disparities in buprenorphine utilization in the United States. Pharmacoepidemiol Drug Saf. 2020;29:708–15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/pds.4984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bennett AS, Elliott L. Naloxone’s role in the national opioid crisis-past struggles, current efforts, and future opportunities. Transl Res. 2021;234:43–57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.trsl.2021.03.001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McGowan CR, Harris M, Platt L, Hope V, Rhodes T. Fentanyl self-testing outside supervised injection settings to prevent opioid overdose: Do we know enough to promote it? Int J Drug Policy. 2018;58:31–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.drugpo.2018.04.017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levengood TW, Yoon GH, Davoust MJ, Ogden SN, Marshall BDN, Cahill SR, et al. Supervised injection facilities as harm reduction: A systematic review. Am J Prev Med. 2021;61:738–49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.amepre.2021.04.017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prescription Drug Monitoring Program Training and Technical Assistance Center, State PDMP profiles and contacts. https://www.pdmpassist.org/State . Accessed 25 Nov 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Gabrielson R, Sanders T. How a $2 roadside drug test sends innocent people to jail. New York Times, July 10, 2016, MM34. http://www.nytimes.com/2016/07/10/magazine/how-a-2-roadside-drug-test-sends-innocent-people-to-jail.html?_r=0 . Accessed 25 Nov 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>American Psychiatric Association: Diagnostic and statistical manual of mental disorders, Fifth edition. Arlington, VA: American Psychiatric Association; 2013.</Citation>
        </Reference>
        <Reference>
          <Citation>International Association of Chiefs of Police. Law enforcement code of ethics. https://www.theiacp.org/resources/law-enforcement-code-of-ethics#:~:text=As%20a%20law%20enforcement%20officer,all%20to%20liberty%2C%20equality%2C%20and . Accessed 26 Nov 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Shefner RT, Sloan JS, Sandler KR, Anderson ED. Missed opportunities: Arrest and court touchpoints for individuals who fatally overdosed in Philadelphia in 2016. Int J Drug Policy. 2020;78:102724.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
